One Nucleus announces new director
Industry expert to support life sciences membership group
One Nucleus announced the appointment of Dr Alan Palmer as a Director. Alan is co-founder and currently Chief Scientific Officer for MS Therapeutics Ltd and has 30 years’ experience in the biotechnology sector in roles spanning academia, research and industry.
Alan has very close ties with the London life science and healthcare community and was a strong supporter of the London Biotechnology Network (LBN), now part of One Nucleus.
Alan Palmer’s career has focused on neurodegenerative disorders and their treatment. He obtained his first degree in Biochemistry from the University of Warwick, with MSc and PhD degrees from the University of London. He has over 30 years of medicines research experience, starting as a Principal Investigator at both the Alzheimer’s disease Research Centre and the Head Injury Research Centre at the University of Pittsburgh. He worked for Wyeth Research in before co-founding Cerebrus Ltd (which later became Vernalis Ltd) and then Pharmidex Pharmaceutical Services Ltd followed by MS Therapeutics Ltd. In 2005 the London Biotechnology Network voted him ‘entrepreneur of the year’. He is a visiting Professor at the School of Pharmacy in London, a Fellow of the Society of Biology and a former Chairman of the Society for Medicines Research. He is also a member of the Scientific Advisory Board of GE Healthcare Medical Diagnostics and has served as a member of the Government’s Biotechnology & Pharmaceuticals Sector Advisory Group.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
